LuTACT

Research Topic: Prostate Cancer

Study Title: Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 in a Prostatectomy Model (LUTACT Trial)

Research Team:
Thomas Hope, MD, Principal Investigator (PI)
Jose Garcia, Clinical Research Coordinator

Sponsor: Novartis

Study Overview

This study is being done to compare two treatments called “radioligand therapies” for high-risk prostate cancer. Radioligand therapy (RLT) is a targeted cancer treatment that combines a tumor-seeking molecule (ligand) with a therapeutic radioactive isotope to deliver precise radiation directly to cancer cells while sparing healthy tissue.  Two types of RLT are used on this study: 177Lu-PSMA-617, an FDA-approved drug for advanced prostate cancer that has spread after other treatments, and 225AcPSMA-617, which is experimental.

Who can join?

Green check mark
  • Histologically confirmed prostate adenocarcinoma
  • Willing to undergo prostatectomy with or without lymph node dissection, and candidate for prostatectomy as determined by urologic oncology.
  • High risk disease as defined as meeting 1 or more of the 3 following criteria: 
    1. Gleason 4+5 disease or higher 
    2. Pelvic nodal metastases on PSMA PET 
    3. Extracapsular extension or seminal vesicle invasion on MRI No evidence of distant metastatic disease as determined by PSMA PET. Nodal disease below the iliac bifurcation (clinical stage N1) is allowed. 
  • Maximum Standardized Uptake Value (SUVmax) in the primary tumor greater than 10 on PSMA PET using 68Ga-PSMA-11 or 18F-DCFPyL. 
Red X
  • Has received prior prostate cancer therapy. 
  • Prior 5-alpha reductase inhibitors (e.g. finasteride, dutasteride) allowed if discontinued at least 3 weeks prior to treatment start

What to Expect During the Study

clipboard
Research activities

Undergoing treatment and 2-3 research scans, several research blood collections, surveys, physician visits.

Globe
Location

In person only

UCSF Mission Bay campus
UCSF China Basin

Stick figures in a circle
How you can help
  • Participation in this study will help researchers compare two radioligand therapies to better understand which treatment delivers more radiation to prostate tumors, how they affect cancer cell death, and how they interact with the immune system. 
  • The knowledge gained may help improve treatment options for future patients with high-risk prostate cancer.

FAQ's

60 months

Visits at screening, Cycle 1 Day 1, 2, 8, and 22, and day of as well as day prior to prostatectomy. Follow ups at Day 42 as well as 6 additional visits up to 60 months after Cycle 1, Day 1.

Up to $300

45

Contact us

[email protected]

Print this page